The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication

Journal of Diabetes and its Complications

Volumn 29, Issue 8, 2015, Pages 1146-1151

  Von Scholten, Bernt Johan ^a   Ørsted, David Dynnes ^b   Svendsen, Anne Louise ^b   Persson, Frederik ^a   Rossing, Peter ^a,c,d  

^a STENO DIABETES CENTER   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

creatinine; glomerular filtration rate; GLP 1; liraglutide; type 2 diabetes

Indexed keywords

CREATININE; EXENDIN 4; GLIMEPIRIDE; GLUCOSE; INSULIN GLARGINE; LIRAGLUTIDE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; ANTIDIABETIC AGENT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT REDUCTION; ALGORITHM; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; DRUG MONITORING; GLOMERULUS FILTRATION RATE; KIDNEY; PATHOPHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY;

ALGORITHMS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG MONITORING; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LIRAGLUTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; WEIGHT LOSS;

EID: 84948712840     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.08.007     Document Type: Article

References (18)

1. E.Y. Berger, S.J. Farber, and D.P. Earle Comparison of the constant infusion and urine collection techniques for the measurement of renal function The Journal of Clinical Investigation 27 1948 710 716
2. B. Bode An overview of the pharmacokinetics, efficacy and safety of liraglutide Diabetes Research and Clinical Practice 97 2012 27 42
3. J. Brochner-Mortensen A simple method for the determination of glomerular filtration rate Scandinavian Journal of Clinical and Laboratory Investigation 30 1972 271 274
4. J.B. Buse, J. Rosenstock, G. Sesti, WE Schmidt, E Montanya, JH Brett, and et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
5. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
6. A. Garber, R. Henry, R. Ratner, PA Garcia-Hernandez, H Rodriguez-Pattzi, I Olvera-Alvarez, and et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
7. J.L. Getty, I.N. Hamdallah, H.N. Shamseddeen, J Wu, RK Low, J Craig, and et al. Changes in renal function following Roux-en-Y gastric bypass: A prospective study Obesity Surgery 22 2012 1055 1059
8. J. Jendle, M.A. Nauck, D.R. Matthews, A Frid, K Hermansen, M Düring, and et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Diabetes, Obesity & Metabolism 11 2009 1163 1172
9. E. Krutzen, S.E. Back, I. Nilsson-Ehle, and P. Nilsson-Ehle Plasma clearance of a new contrast agent, iohexol: A method for the assessment of glomerular filtration rate The Journal of Laboratory and Clinical Medicine 104 1984 955 961
10. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group Annals of Internal Medicine 130 1999 461 470
11. A.S. Levey, L.A. Stevens, C.H. Schmid, YL Zhang, AF Castro III, HI Feldman, and et al. A new equation to estimate glomerular filtration rate Annals of Internal Medicine 150 2009 604 612
12. J.C. Lieske, M.L. Collazo-Clavell, M.G. Sarr, A.D. Rule, E.J. Bergstralh, and R. Kumar Gastric bypass surgery and measured and estimated GFR in women American Journal of Kidney Diseases 64 2014 663 665
13. M. Marre, J. Shaw, M. Brändle, WM Bebakar, NA Kamaruddin, J Strand, and et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabetic Medicine 26 2009 268 278
14. M. Nauck, A. Frid, K. Hermansen, NS Shah, T Tankova, IH Mitha, and et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 32 2009 84 90
15. R.E. Pratley, M.A. Nauck, T. Bailey, E Montanya, S Filetti, AJ Garber, and et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: A randomized, open-label trial Diabetes Care 35 2012 1986 1993
16. D. Russell-Jones, A. Vaag, O. Schmitz, BK Sethi, N Lalic, S Antic, and et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial Diabetologia 52 2009 2046 2055
17. M. Wyss, and R. Kaddurah-Daouk Creatine and creatinine metabolism Physiological Reviews 80 2000 1107 1213
18. B. Zinman, J. Gerich, J.B. Buse, A Lewin, S Schwartz, P Raskin, and et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) Diabetes Care 32 2009 1224 1230